Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 12/20 | 0.47 |
| ▸ | RAF1 | P04049 | 3/20 | 0.37 |
| ▸ | BRAF | P15056 | 3/20 | 0.37 |
| ▸ | UBE2M | P61081 | 1/20 | 0.35 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CASR | P41180 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6156645 | 0.90 | F10 (0.48) | F10RAF1BRAF | |
| SCHEMBL6156079 | 0.88 | F10 (0.44) | F10CASR | |
| SCHEMBL6156928 | 0.88 | TPSAB1 (0.36) | F10UBE2MDCUN1D1 | |
| SCHEMBL6157122 | 0.84 | F10 (0.47) | F10RAF1BRAFCYP2C9 | |
| SCHEMBL6156081 | 0.83 | F10 (0.43) | F10RAF1BRAF | |
| SCHEMBL6156132 | 0.79 | F10 (0.47) | F10RAF1BRAF | |
| SCHEMBL6156954 | 0.78 | SMN1; SMN2 (0.51) | CYP2C9 | |
| SCHEMBL6156026 | 0.77 | TRPV1 (0.37) | F10UBE2MDCUN1D1 | |
| SCHEMBL6156664 | 0.76 | TP53 (0.40) | F10CYP2C9 | |
| SCHEMBL6156412 | 0.75 | KDM1A (0.41) | CASR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050171102-A1 | Semicarbazide derivatives for combating thromboembolic diseases | MERCK PATENT GMBH (DE) | 2005-08-04 | — | — | US | claimed |
| US-20050171102-A1 | Semicarbazide derivatives for combating thromboembolic diseases | MERCK PATENT GMBH (DE) | 2005-08-04 | — | — | US | disclosed |
| EP-1501814-A1 | SEMICARBAZIDE DERIVATIVES FOR COMBATING THROMBOEMBOLIC DISEASES | MERCK PATENT GmbH (DE) | 2005-02-02 | — | — | EP | disclosed |
| WO-2003093254-A1 | SEMICARBAZIDE DERIVATIVES FOR COMBATING THROMBOEMBOLIC DISEASES | MERCK PATENT GMBH (DE) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171102-A1 | Semicarbazide derivatives for combating thromboembolic diseases | SERPINC1, F11, F12 | F10 6/4885RAF1 1083/4885BRAF 1778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.